Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2- Locally Advanced, Metastatic Breast Cancer”

74 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 74 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Not applicableStudy completedNCT05505175
What this trial is testing

Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

Who this might be right for
Breast CancerBreast Carcinoma
Pfizer 120
Not applicableStudy completedNCT05452798
What this trial is testing

A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark

Who this might be right for
Breast Cancer
Pfizer 1,054
Not applicableStudy completedNCT03921866
What this trial is testing

UK Ibrance Patient Program (IPP) Study

Who this might be right for
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Pfizer 191
Early research (Phase 1)Study completedNCT02154776
What this trial is testing

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

Who this might be right for
Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals 13
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Large-scale testing (Phase 3)Looking for participantsNCT05744687
What this trial is testing

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd 374
Large-scale testing (Phase 3)Ended earlyNCT03326674
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 685
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Large-scale testing (Phase 3)Not Yet RecruitingNCT07340658
What this trial is testing

Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Rovi Pharmaceuticals Laboratories 300
Early research (Phase 1)Study completedNCT01857193
What this trial is testing

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 132
Large-scale testing (Phase 3)Looking for participantsNCT06383767
What this trial is testing

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Qilu Pharmaceutical Co., Ltd. 378
Testing effectiveness (Phase 2)UnknownNCT03910712
What this trial is testing

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

Who this might be right for
Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast+3 more
Peking Union Medical College Hospital 250
Not applicableStudy completedNCT06311383
What this trial is testing

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 2,610
Large-scale testing (Phase 3)UnknownNCT05433480
What this trial is testing

BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Betta Pharmaceuticals Co., Ltd. 274
Large-scale testing (Phase 3)Not Yet RecruitingNCT07393321
What this trial is testing

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical 210
Testing effectiveness (Phase 2)Looking for participantsNCT05075512
What this trial is testing

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasm Female
Zhejiang Cancer Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT06827613
What this trial is testing

Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
Marengo Therapeutics, Inc. 50
Large-scale testing (Phase 3)Ended earlyNCT01633060
What this trial is testing

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 432
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Load More Results